Venous thromboembolism (VTE), encompassing pulmonary embolism (PE) and deep vein thrombosis (DVT), represents a significant global health burden due to high morbidity and mortality rates associated with the condition [1]. Although short-term mortality in VTE patients has been extensively studied, reports on mortality outcomes beyond the initial period are sparse. The long-term mortality rates reported across studies vary widely, ranging from 9% reported in some cohorts [2] to as high as 50% in others [3].
